Bladder Cancer
Jan 17, 2025, 09:16
Using cDNA testing to guide immunotherapy for Bladder Cancer post-surgery – PRIMR
PRIMR shared a post on X:
“New series.
Introducing the MODERN Trial: using cDNA testing to guide immunotherapy for Bladder Cancer post-surgery, detecting recurrence early, and tailoring treatment to improve outcomes.
Matt Galsky, Director of Genitourinary Medical Oncology at Tisch Cancer Institute and Professor of Medicine at Icahn School of Medicine at Mount Sinai, shared PRIMR’s post adding:
“Please support Alliance A032103 to define the role of ctDNA-based adjuvant therapy decision-making in Bladder Cancer.”
More posts featuring PRIMR and Matt Galsky.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 11, 2025, 22:51
May 11, 2025, 18:14
May 11, 2025, 18:05
May 11, 2025, 17:07
May 11, 2025, 16:57
May 11, 2025, 16:49